Appeals court rules against NIH’s indirect cost cut plan news2026-01-05T23:54:56+00:00January 5th, 2026|Endpoints News|
FDA raises new questions with Sanofi’s MS drug in release of rejection letternews2026-01-05T20:22:17+00:00January 5th, 2026|Endpoints News|
HHS urges Supreme Court to decline AstraZeneca’s petition over Medicare price negotiationsnews2026-01-05T19:42:19+00:00January 5th, 2026|Endpoints News|
US to stop recommending six vaccines for all kids, prioritizing individual choice and higher-risk groupsnews2026-01-05T19:02:32+00:00January 5th, 2026|Endpoints News|
Crinetics reports robust full-quarter sales for rare disease drug Palsonifynews2026-01-05T18:14:15+00:00January 5th, 2026|Endpoints News|
Zenas BioPharma’s Phase 3 autoimmune disease readout disappointsnews2026-01-05T16:21:59+00:00January 5th, 2026|Endpoints News|
Moderna seeks flu vaccine approvals; Neumora Alzheimer’s datanews2026-01-05T16:08:37+00:00January 5th, 2026|Endpoints News|
Argenx to elevate Massey to CEO as it expands rare disease businessnews2026-01-05T15:30:16+00:00January 5th, 2026|Endpoints News|
Sanofi doubles down on Earendil in $160M near-term dealnews2026-01-05T15:03:58+00:00January 5th, 2026|Endpoints News|
Aktis Oncology eyes $181M listing to start industry’s anticipated IPO reboundnews2026-01-05T12:11:50+00:00January 5th, 2026|Endpoints News|
